Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS
Inhalt archiviert am 2024-05-28

Protein biomarker for the prediction of response to endocrine treatment in breast cancer patients

Ziel

Classical pathologic parameters have been used to inform adjuvant clinical treatment choices for early breast cancer patients. There remain a significant number of patients however, who despite a reportedly favourable prognostic profile, experience metastatic disease. Elucidation of the mechanisms of tumour adaptability and the identification of predictive markers of early recurrence is the basis of personalized medicine. Work from our group has established the developmental protein HOXC11 as a powerful predictor of resistance to endocrine treatment in breast cancer patients .The aim of this project is to establish a joint industry-academia partnership to produce a commercially viable and clinically validated predictive assay/kit which based on the use of HOXC11 as a predictive biomarker of poor response to endocrine treatment in breast cancer patients.

Wissenschaftliches Gebiet (EuroSciVoc)

Programm/Programme

Thema/Themen

Aufforderung zur Vorschlagseinreichung

FP7-PEOPLE-2012-IAPP
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

MC-IAPP - Industry-Academia Partnerships and Pathways (IAPP)

Koordinator

ROYAL COLLEGE OF SURGEONS IN IRELAND
EU-Beitrag
€ 390 695,04
Adresse
ST STEPHEN GREER 123
D02 YN77 DUBLIN 2
Irland
Region
Ireland Eastern and Midland Dublin
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
Keine Daten

Beteiligte (1)